Integra Lifesciences Bolsa (NASDAQ: IART)

Integra Lifesciences (NASDAQ:IART) Bolsa

Integra Lifesciences

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

WIIM

IART

Integra LifeSciences shares are trading higher after the company reported better-than-expected Q2 financial results,

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) affirms FY2025 Adj EPS guidance from $2.19-$2.29 to $2.19-$2.29 vs $2.24 analyst estimate. Narrows FY2025 sales outlook from $1.650 billion-$1.715 billion to $1.655 billion-$1.680 billion vs $1.667 billion estimate.

News

Guidance

Integra Lifesciences Affirms FY2025 Adj EPS Guidance of $2.19-$2.29 vs $2.24 Est; Narrows FY2025 Sales Guidance from $1.650B-$1.715B to $1.655B-$1.680B vs $1.667B Est

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) is looking for Q3 Adj EPS of $0.40-$0.45 vs $0.58 analyst estimate. sees sales of $410.000 million-$420.000 million vs $418.831 million analyst estimate.

Integra Lifesciences Sees Q3 Adj EPS $0.40-$0.45 vs $0.58 Est; Sees Sales $410.000M-$420.000M vs $418.831M Est

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.43 by 4.17 percent. This is a 28.57 percent decrease over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $415.605 million which beat the analyst consensus estimate of $395.067 million by 5.20 percent. This is a 0.61 percent decrease over sales of $418.175 million the same period last year.

Earnings

Earnings Beats

Integra Lifesciences Q2 Adj. EPS $0.45 Beats $0.43 Estimate, Sales $415.605M Beat $395.067M Estimate

AAMI

AAPL

ABBV

ACCO

AGCO

AGIO

ALGM

ALNY

AMZN

APLS

APPF

APTV

ARGX

ASUR

ATEC

ATHM

AUPH

AXTI

BBVA

BCPC

BFAM

BIGC

BIIB

BJRI

BLDR

BOOT

BSAC

CABO

CACC

CCCS

CCEC

CDRO

CIGI

CLAR

CMCSA

CMPS

CMRE

COHN

COHU

COIN

COLM

CORT

CRAI

CUBE

CVCO

CWST

DFIN

DINO

DOUG

DSGR

Earnings Scheduled For July 31, 2025

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/applicator-recall-integra-lifesciences-removes-micromyst-applicators-due-potential-sterility#:~:text=Reason%20for%20Recall,the%20products%20were%20effectively%20sterilized" title="https://www.fda.gov/medical-devices/medical-device-recalls/applicator-recall-integra-lifesciences-removes-micromyst-applicators-due-potential-sterility#:~:text=Reason%20for%20Recall,the%20products%20were%20effectively%20sterilized">https://www.fda.gov/medical-devices/medical-device-recalls/applicator-recall-integra-lifesciences-removes-micromyst-applicators-due-potential-sterility#:~:text=Reason%20for%20Recall,the%20products%20were%20effectively%20sterilized</a>.

Biotech

General

FDA Announces Applicator Recall: Integra LifeSciences Removes MicroMyst Applicators Due To Potential Sterility Concerns

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/cranial-drill-recall-integra-lifesciences-recalls-codman-disposable-perforators-due-risk-device" title="https://www.fda.gov/medical-devices/medical-device-recalls/cranial-drill-recall-integra-lifesciences-recalls-codman-disposable-perforators-due-risk-device">https://www.fda.gov/medical-devices/medical-device-recalls/cranial-drill-recall-integra-lifesciences-recalls-codman-disposable-perforators-due-risk-device</a>

'Cranial Drill Recall: Integra LifeSciences Recalls Codman Disposable Perforators Due to Risk of Device Disassembly' - FDA

Integra LifeSciences Announces First Patient Has Enrolled In Acclarent AERA Pediatric Registry

JMP Securities analyst David Turkaly maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Market Outperform and lowers the price target from $35 to $25.

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $25

JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Underweight and lowers the price target from $24 to $12.

JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $12

Wells Fargo analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Equal-Weight and lowers the price target from $25 to $13.

Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 52.8% to $0.7 during Monday's regular session. The company's market cap stands at $4.2 million. </li>
<li>Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) stock moved upwards by 35.6% to $2.32. The market value of their outstanding shares is at $337.2 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) stock moved upwards by 33.33% to $2.4. The company's market cap stands at $11.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 31.91% to $80.8. The company's market cap stands at $1.0 billion. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares rose 23.54% to $4.25. The company's market cap stands at $62.9 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 23.2% to $0.31. The market value of their outstanding shares is at $4.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock decreased by 26.4% to $12.4 during Monday's regular session. The company's market cap stands at $957.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares decreased by 23.47% to $1.37. The market value of their outstanding shares is at $18.2 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 22.46% to $0.58. The market value of their outstanding shares is at $6.6 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock fell 21.2% to $2.38. The market value of their outstanding shares is at $139.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) stock declined by 19.49% to $2.04. The market value of their outstanding shares is at $1.8 billion. </li>
<li>PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) stock declined by 17.48% to $41.22. The market value of their outstanding shares is at $3.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIRS

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CYCC

IBRX

IMMP

NCNA

PTCT

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.2% on Monday.
The Dow traded up 0.21% to 41,406.25 while the NASDAQ fell 0.41% to 17,903.64. The S&amp;P 500 also fell, dropping, 0.26% to 5,671.90.
Check This Out: <a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a>
Leading and Lagging Sectors Industrials shares rose by 0.2% on Monday.
In trading on Monday, energy stocks dipped by 1.9%.
Top Headline
The ISM services PMI rose to 51.6 in April versus a nine-month low level of 50.8 in the previous month March and topping market estimates of 50.6.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Hyperscale Data, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NASDAQ">GPUS</a>) shares shot up 202% to $4.14 after the company issued first-quarter and FY25 sales guidance.</li>
<li>Shares of Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) got a boost, surging 25% to $61.70 after the company agreed to be acquired by 3G Capital for $63 per share.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) shares were also up, gaining 12% to $10.01 after the company reported a first-quarter sales beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) shares dropped 29% to $11.94 after the company reported a first-quarter adjusted EPS miss and cut its FY25 adjusted EPS guidance.</li>
<li>Shares of PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) were down 18% to $40.87. The company announced results from the Phase 2 PIVOT-HD study of PTC518 in Stage 2 and Stage 3 Huntington&#8217;s disease patients.</li>
<li>TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) was down, falling 16% to $36.53 after the company reported worse-than-expected first-quarter EPS results.</li>
</ul>
Commodities In commodity news, oil traded down 2.2% to $57.00 while gold traded up 2.5% at $3,323.40.
Silver traded up 0.6% to $32.455 on Monday, while copper rose 0.3% to $4.6875.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.06%, while Spain's IBEX 35 Index gained 0.40%. Germany's DAX 40 rose 0.87% and France's CAC 40 fell 0.58% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with India's BSE Sensex rising 0.37%.
Economics
<ul>
<li>The S&amp;P Global services PMI was revised lower to 50.8 in April 2025 compared to a preliminary reading of 51.4.</li>
<li>The ISM services PMI rose to 51.6 in April versus a nine-month low level of 50.8 in the previous month March and topping market estimates of 50.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45192437/how-to-earn-500-a-month-from-williams-companies-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Williams Companies Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Intraday Update

Markets

Trading Ideas

BCRX

GPUS

TGTX

Crude Oil Falls Over 2%; ISM Services PMI Rises In April

Integra LifeSciences shares are trading lower after the company reported a Q1 adjusted EPS miss, issued Q2 guidance below estimates, and cut its FY25 adjusted EPS guidance.

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) lowers FY2025 Adj EPS guidance from $2.41-$2.51 to $2.19-$2.29 vs $2.46 analyst estimate. Affirms FY2025 sales outlook from $1.65 billion-$1.72 billion to $1.65 billion-$1.72 billion vs $1.68 billion estimate.

Integra Lifesciences Lowers FY2025 Adj EPS Guidance from $2.41-$2.51 to $2.19-$2.29 vs $2.46 Est; Affirms FY2025 Sales Guidance of $1.65B-$1.72B vs $1.68B Est

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) is looking for Q2 Adj EPS of $0.40-$0.45 vs $0.57 analyst estimate. sees sales of $390.000 million-$400.000 million vs $417.04 million analyst estimate.

Integra Lifesciences Sees Q2 Adj EPS $0.40-$0.45 vs $0.57 Est; Sees Sales $390.000M-$400.000M vs $417.04M Est

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported quarterly earnings of $0.41 per share which missed the analyst consensus estimate of $0.43 by 4.65 percent. This is a 25.45 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $382.65 million which beat the analyst consensus estimate of $381.17 million by 0.39 percent. This is a 3.74 percent increase over sales of $368.87 million the same period last year.

Earnings Misses

Integra Lifesciences Q1 Adj. EPS $0.41 Misses $0.43 Estimate, Sales $382.65M Beat $381.17M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

AXSM

BCSF

BNTX

BRBR

BRCC

BWXT

CERT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

HSTM

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NBIX

NGVT

NMFC

NSSC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and lowers the price target from $26 to $19.

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $19

Argus Research analyst David Toung upgrades Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) from Hold to Buy.

Upgrades

Argus Research Upgrades Integra Lifesciences to Buy

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

Health Care

Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry

Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025

Comments

Integra Lifesciences

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL